Zobrazeno 1 - 10
of 116
pro vyhledávání: '"olokizumab"'
Autor:
A. V. Fedorova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, A. A. Akimova, N. A. Ilyina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev
Publikováno v:
Современная ревматология, Vol 18, Iss 3, Pp 25-31 (2024)
In the context of the new coronavirus infection (NCI) COVID-19 pandemic, the rheumatological community is facing new challenges in the treatment of immune-inflammatory rheumatic diseases (IIRDs). It has been shown that rheumatological patients have a
Externí odkaz:
https://doaj.org/article/7e2094d9d4c04da1883375affe7e3353
Autor:
A. M. Lila, L. I. Alekseeva, E. A. Taskina, N. G. Kashevarova, E. P. Sharapova, E. A. Strebkova, N. M. Savushkina, A. R. Khalmetova, V. A. Nesterenko, A. S. Avdeeva, E. Yu. Samarkina, M. E. Diatroptov, O. G. Alekseeva
Publikováno v:
Современная ревматология, Vol 18, Iss 3, Pp 14-24 (2024)
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with knee osteoarthritis (OA) with synovitis, persistent pain and ineffectiveness of previous conservative therapy. Material and methods. The study included 15 patients
Externí odkaz:
https://doaj.org/article/a2d5570a9a8b437ea513c76f3516eedb
Autor:
Alexey D. Meshkov, Alexey L. Maslyansky, Nikolay M. Bulanov, Ekaterina E. Filatova, Pavel I. Novikov, Anton V. Naumov, Olga N. Tkacheva
Publikováno v:
Научно-практическая ревматология, Vol 62, Iss 4 (2024)
Glucocorticoids are the basis for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), however, their long-term use is associated with a number of well-known side effects. Despite the fact that a significant number of patient
Externí odkaz:
https://doaj.org/article/f912550e6fa242f3a260a193b19094e7
Autor:
N. A. Lapkina, A. A. Baranov, N. E. Abaytova, E. A. Leontyeva, N. V. Yaltseva, A. S. Shutov, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 5, Pp 554-561 (2023)
The aim of the study was to evaluate in real clinical practice the effectiveness of therapy with an interleukin-6 inhibitor (olokizumab) in patients with rheumatoid arthritis (RA) in terms of clinical and laboratory activity of the disease, as well a
Externí odkaz:
https://doaj.org/article/d170c004cde24ad8883b3c8ef65dc9ac
Autor:
N. A. Lapkina, A. A. Baranov, N. Yu. Levshin, A. A. Kolinko, L. A. Mineeva, A. S. Artyuhov, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 4, Pp 475-484 (2023)
The aim of the study was to investigate the dynamics of clinical and laboratory parameters of inflammatory disease activity and cytokines in patients with rheumatoid arthritis (RA) against the background of olokizumab (OKZ) treatment.Materials and me
Externí odkaz:
https://doaj.org/article/77fc72293f0940d180661a4655bd6594
Autor:
A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 3, Pp 307-319 (2023)
Aim. Switching to another biologic with the same mode of action provides greater opportunity for long-term management of patients with rheumatoid arthritis (RA). In clinical practice, especially in the context of the COVID-19 pandemic, such switching
Externí odkaz:
https://doaj.org/article/cf4c379b9f39436f8f4c659e8754ef3b
Autor:
T. A. Lisitsyna, A. A. Abramkin, D. Yu. Veltishchev, O. F. Seravina, O. B. Kovalevskaya, A. B. Borisova, V. G. Ignatiev, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 2, Pp 188-198 (2023)
Background. Interleukin (IL) 6 plays an important role in the pathogenesis of comorbid rheumatoid arthritis (RA) depression, and IL-6 inhibitors (i) used to treat RA patients may have an antidepressant effect.Objective – to evaluate the effectivene
Externí odkaz:
https://doaj.org/article/21f9c854dca64839a7b03985a510c0d8
CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
Autor:
E. V. Tavlueva, E. V. Zernova, M. P. Kutepova, N. E. Kostina, V. S. Lesina, D. R. Mould, K. Ito, A. V. Zinchenko, A. N. Dolgorukova, M. V. Nikolskaya, M. S. Lemak, O. V. Filon, M. Yu. Samsonov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 10, Iss 5, Pp 460-471 (2022)
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phas
Externí odkaz:
https://doaj.org/article/96b8864adb544463a121630b4d6598a5
Publikováno v:
Acta Biomedica Scientifica, Vol 7, Iss 5-2, Pp 86-95 (2022)
Background. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim. To study in real clinical pr
Externí odkaz:
https://doaj.org/article/198b91e0cdfb4b1e8ebb3db9e7373f9e
Autor:
E. S. Kuvardin, D. Yu. Andreev, P. A. Yastrebov, V. Yu. Myachikova, D. V. Bukhanova, D. V. Karpova, K. N. Malikov, M. Yu. Samsonov, A. L. Maslyanskiy
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 5, Pp 603-608 (2022)
Treatment algorithms for systemic sclerosis have not been completely developed. Effectivity of medications are usually used in clinical practice has a low level of evidence. Therefore, it is necessary to find a new treatment approaches for this nosol
Externí odkaz:
https://doaj.org/article/74c94962383a46af9b50fe955058831b